Falk Gastro Info 11/2018

Video report

Enquired:
Alex Straumann, Olten, Switzerland

• Why is treatment of EoE necessary?
• How can EoE be treated?

Video report to the discussion with Prof. Dr. Alex Straumann, Olten, Switzerland at Symposium 208 – “Eosinophilic Esophagitis – Medical and Dietary Treatment”, October 4 – 5, 2017 in Berlin (Germany).
© Falk Foundation e.V., Freiburg. All rights reserved.

Please switch on your loudspeakers!

Link to Falk Mediacenter

Latest research in brief:

Bowel

Text:

Targownik LE et al, Am J Gastroenterol. 2018;113(8):1206–16

Significance of immunomodulator monotherapy for inflammatory bowel diseases (IBD): Results of a large Canadian cohort study reveal that almost half of IBD patients are treated with a monotherapy of immunomodulators. Approx. one third of these patients achieve a sustained clinical response for over 5 years.

Link to text

Text:

Bach Larsen M et al, Gastroenterology. 2018;155(1):99–106

Effectiveness of colorectal cancer (CRC) screening in detecting earlier-stage disease: Nationwide cohort study in Denmark demonstrates that inviting individuals to undergo fecal immunochemical blood test-based screening leads to detection of almost 2-fold more CRC cases than not inviting indviduals.

Link to text

Text:

Nakajima A et al, Lancet Gastroenterol Hepatol. 2018;3(8):537–47

Novel therapeutic approach to treat functional constipation: A phase III trial indicates that elobixibat, an orally available inhibitor of ileal bile acid transport, resolved constipation in the short-term and is well tolerated in the long-term.

Link to text

Liver Biliary Tracts

Text:

Belli LS et al, J Hepatol. 2018;69(4):810–7
Kim D et al, Gastroenterology. 2018;155(4):1154–63.e3

Hepatitis C: Two current studies from Europe and the US, respectively, clearly demonstrate that direct-acting antiviral therapy for hepatitis C led to a decrease in hepatitis C-related liver transplantation, an improved survival after hepatitis C-related liver transplantation, and a decrease in hepatitis C-related mortality. Liver transplantation and mortality due to alcohol and non-alcoholic fatty liver disease, however, are increasing.

Link to text

Text:

Wong LL et al, Hepatology. 2018;68(4):1487–97

Autoimmune hepatitis: A current cohort study confirms a substantial impact of autoimmune hepatitis on health-related quality of life. In this context, the use of corticosteroids has a prominent role.

Link to text

Text:

Thuluvath PJ et al, J Hepatol. 2018;69(4):818–25

Liver transplantation: The Model of End-stage Liver Disease (MELD) score is an accepted indicator for the urgency of liver transplantation. In contrast, well-established predictors for the chances of success of liver transplantation are missing. A current study indicates that the Karnofsky performance status may be a feasible predictor of graft and patient survival after liver transplantation.

Link to text

Oesophagus Stomach Duodenum

Text:

Warners MJ et al, Am J Gastroenterol. 2018;113(6):836–44

Natural course and consequences of eosinophilic esophagitis (EoE): A large retrospective cohort study confirms that EoE progresses from an inflammatory to a fibrostenotic phenotype. With each additional year of undiagnosed EoE the risk of stricture presence increases with 9%.

Link to text

Text:

Jankowski JAZ et al, Lancet. 2018;392(10145):400–8

Chemoprevention for Barrett’s esophagus: High-dose proton-pump inhibitors (PPI) and aspirin, especially in combination, significantly and safely improved outcomes in patients with Barrett’s esophagus (mortality, esophageal adenocarcinoma or high-grade dysplasia). The number needed to treat was 34 for PPI and 43 for aspirin.

Link to text

Text:

Shitara K et al, Lancet. 2018;392(10142):123–33

Second-line chemotherapy for advanced gastric or gastroesophageal junction cancer: The PD-1 inhibitor pembrolizumab did not significantly improve overall survival compared with paclitaxel in a phase III trial, but had a better safety profile.

Link to text

Pancreas

Text:

Canto MI et al, Gastroenterology. 2018;155(3):740–51.e2

Risk of neoplastic progression in individuals at high risk for pancreatic cancer: Pancreatic cancer and high-risk precursors in patients undergoing long-term surveillance in 7% within 5 years with a neoplastic progression rate of 1,6% per year. Most tumors detected during surveillance are resectable and the overall survival is good.

Link to text

International Symposia and Workshops

Symposium 214

IBD: From Pathophysiology to Personalized Medicine

March 29–30, 2019, Oxford, United Kingdom
Examination Schools, 75-81, High Street, Oxford OX1 4BG, United Kingdom

Program

Registration

Online registration

Workshop

From Viral Hepatitis to Chronic Inflammation and Liver Cancer

February 21–22, 2019, Heidelberg, Germany
Hörsaalzentrum Chemie, Chemisches Institut, Im Neuenheimer Feld 252, 69120 Heidelberg, Germany

Program